An interventional study of Upper lobectomy with pulmonary ligament division and Pulmonary ligament preservation post lobectomy in Lobectomy, Lung Cancer Non-Small Cell Cancer (NSCLC) and Lung Volume, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Carcinoma, Non-Small-Cell Lung with a site in Egypt — none open to participants now, 1 under way, 1 of them phase 3. Carcinoma, Non-Small-Cell Lung · Egypt.
Among the 29 studies in Carcinoma, Non-Small-Cell Lung with a site in Egypt, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2024, is the only one with no phase, and was the 29th registered.
7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 29 studies in Carcinoma, Non-Small-Cell Lung with a site in Egypt is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 12 · Phase 4 3
First in 1995; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 62 across 6,028 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 263 across the 19 interventional studies, 139 across the 10 observational. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 29 have an industry lead sponsor. The 10 most frequent:
Ain Shams University is the lead sponsor of 1,956 studies on the registry; 431 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ain Shams University has 6 studies filed under Carcinoma, Non-Small-Cell Lung — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Carcinoma, Non-Small-Cell Lung with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study looks at two different surgical techniques used during lung surgery (upper lobectomy). Surgeons may either divide or preserve a thin tissue band called the pulmonary ligament. The investigators want to understand how this choice affects recovery, including changes in lung size, airway shape, and symptoms such as cough. Forty patients took part, with half receiving ligament division and the other half with ligament preservation post upper lobectomy. Lung volume and airway changes were measured using CT scans, and cough scores were recorded after surgery. The study also noted one patient in the division group who developed a space problem (pneumothorax) two weeks after surgery. The goal is to learn which approach may help patients recover more comfortably and reduce postoperative symptoms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
inferior pulmonary ligament dissection post lobectomy
Procedure: Upper lobectomy with pulmonary ligament division
the inferior pulmonary ligament will be preserved after upper lobectomy
Procedure: Pulmonary ligament preservation post lobectomy
Division Group (Experimental Arm): In this group, the inferior pulmonary ligament is surgically divided during upper lobectomy. Division removes the ligament's natural support, allowing the residual lung to expand and shift more freely within the pleural cavity. This maneuver is hypothesized to influence postoperative bronchial geometry, lung-volume reduction, and cough severity. Unlike standard lobectomy protocols where ligament management is not isolated, this intervention specifically evaluates the impact of ligament division as the primary variable of interest.
Preservation Group (Comparator Arm): In this group, the inferior pulmonary ligament is left intact during upper lobectomy. Preserving the ligament maintains the natural anatomical support of the residual lung and may reduce postoperative displacement or distortion of the bronchial tree. Unlike other thoracic surgical interventions that routinely divide the ligament, this approach specifically evaluates whether preservation minimizes postoperative lung-volume reduction, cough severity, and space-related complications. The preservation strategy therefore serves as a comparator to ligament division, isolating the effect of ligament management on postoperative anatomical and clinical outcomes.
Bronchial Angle
The change in bronchial angulation pre- and post-operatively
Time frame: From enrollment post operative to the end of treatment at 2 weeks
Lung Volume
The difference in lung volume pre- and post-operatively using CT 3D reconstructive imaging
Time frame: From enrollment post operative to the end of treatment at 2 weeks
Irretractable post lobectomy cough
Development of post-operative symptomatic cough (unresponsive to expectorants or mucolytics) / measured using the COAT sheet for cough assessment
Time frame: post intervention by 2-3 weeks
length of hospital stay
The length of hospital stay per patient in days post operative
Time frame: From completion of the intervention until the first chest X-ray showing normal findings and no air leak, assessed up to 21 days after the intervention.
Plan to share: Yes — population demographic data and clinical characteristics of the studied patients
Supporting information: Study protocol, Informed consent form
Time frame: May 1st 2026 till end of December 2026
Access criteria: Authors, editors and Faculty registered colleagues
Ran from Feb 2024 to primary completion in Feb 2026, 24 months.
Of 344 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 98. This study's 24 months is below that.
Counting every sponsor, half of 360 studies reached it within 51 months; a quarter within 26 and three quarters within 97.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →